CRL-40,940, also known as Flmodafinil or Bisfluoromodafinil, is a wakefulness-promoting agent structurally related to modafinil. It is a selective dopamine reuptake inhibitor (DRI) with potential applications in treating conditions such as chronic fatigue syndrome, idiopathic hypersomnia, narcolepsy, ADHD, and Alzheimer’s disease.
Unlike modafinil, flmodafinil does not induce cytochrome P450 enzymes, reducing the risk of drug interactions. Flmodafinil is an enantiopure derivative of modafinil, with the (R)-bis(4-fluoro) phenyl ring-substituted structure.
It is currently in preclinical development for chronic fatigue syndrome, while development for other conditions has been discontinued.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | FlModafinil, Fl-Modafinil, Bisfluoromodafinil, Lauflumide, Acetamide, 2-[[bis(4-fluorophenyl)methyl]sulfinyl]- |
|---|---|
| IUPAC Name | 2-[bis(4-fluorophenyl)methylsulfinyl]acetamide |
| CAS | 90280-13-0 |
| Molecular Weight | 309.3 |
| Molecular Formula | C15H13F2NO2S |
| SMILES | C1=CC(=CC=C1C(C2=CC=C(C=C2)F)S(=O)CC(=O)N)F |